MedTrace Logo

Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Plasma Cell Tumors

NCT04665076 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2020-12-11

No results posted yet for this study

Summary

This study is a multi-center, non-randomized, single-arm, open clinical trial.

Conditions

  • Plasma Cell Tumors

Interventions

BIOLOGICAL

Auto CAR-T

Biological: Auto CAR-T

DRUG

Cyclophosphamide,Fludarabine

Drug: Cyclophosphamide,Fludarabine

PROCEDURE

Leukapheresis

Leukapheresis

Sponsors & Collaborators

  • Hebei Medical University Fourth Hospital

    collaborator OTHER

  • Hebei Senlang Biotechnology Inc., Ltd.

    lead INDUSTRY

Principal Investigators

  • Baoen Shan, PhD & MD · Hebei Medical University Fourth Hospital

  • Lihong Liu, PhD & MD · Hebei Medical University Fourth Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
14 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-22
Primary Completion
2023-10-21
Completion
2025-10-21

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04665076 on ClinicalTrials.gov